The ruling is interlocutory — no immediate financial liability, but it revives a failure-to-warn theory that could pressure Amgen to settle or face discovery on CBE label-change obligations. Monitor for: (1) Amgen's petition for rehearing or certiorari; (2) settlement discussions; (3) any FDA action on Aimovig's label based on the cited studies. The case is in early stages; the most material risk is a future adverse verdict or FDA-mandated label change.
Price Chart
Executive Summary
The First Circuit partially reversed the district court's dismissal of a wrongful death suit against Amgen concerning its migraine drug Aimovig (erenumab). The appellate panel affirmed that pre-approval failure-to-warn claims are preempted, but reversed the denial of leave to amend, finding the plaintiff plausibly alleged that four post-approval studies (Rehni, Liu, Sorby-Adams, Zhai) could constitute 'newly acquired information' enabling a CBE label change. The case is remanded for further proceedings on this narrower theory, reopening litigation risk for Amgen on a drug with billions in annual sales.
Court Ruling Details
Key Facts
- First Circuit reversed district court's denial of leave to amend, allowing plaintiff to pursue a post-approval CBE label-change theory based on four studies suggesting CGRP antagonism may worsen cerebral injury outcomes.
- The appellate panel found the plaintiff plausibly alleged that the Rehni, Liu, Sorby-Adams, and Zhai studies constitute 'newly acquired information' not previously submitted to the FDA.
- The court held that at the pleading stage, the studies provide a reasonable basis for a causal association between CGRP blockade and worsened outcomes in patients with seizure/cerebrovascular history.
- The pre-approval failure-to-warn claims were affirmed as preempted — Amgen could not unilaterally change the label during the BLA process.
- Aimovig (erenumab) is a blockbuster migraine prevention biologic; the case concerns a single patient death but could set precedent for future labeling-related litigation.
- No damages were awarded; the ruling is interlocutory — the case returns to district court for further proceedings.
Financial Impact
No damages awarded; litigation risk reopened on Aimovig, which had $2.9B in 2023 U.S. sales (Amgen's 2023 10-K). Potential exposure includes future verdicts, settlement costs, and label changes that could impact prescribing patterns.
Risk Factors
- Potential for adverse jury verdict or settlement if the case proceeds to trial on the CBE theory
- FDA may independently review the cited studies and require label changes for Aimovig or other CGRP antagonists
- Precedent could encourage additional failure-to-warn lawsuits against Amgen and other CGRP drug manufacturers
- Discovery may reveal internal Amgen documents about post-approval awareness of CGRP-related risks
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-758682fbdc-AMGN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Court Ruling | $438.34 $447.28 | ▲ +2.04% | ▲ +3.22% | $439.26 (+0.21%) |
Oct 9, 2026 17d ago | Court Ruling | $417.57 $412.84 | ▲ +1.13% | ▲ +1.12% | $439.26 (−5.19%) |
Sep 10, 2026 6w ago | ANALYST-DOWNGRADE | $382.47 $377.35 | ▲ +1.34% | ▲ +2.19% | $439.26 (−14.85%) |
Sep 8, 2026 6w ago | ANALYST-DOWNGRADE | $393.17 $391.27 | ▲ +0.48% | ▲ +0.02% | $439.26 (−11.72%) |
Aug 14, 2026 10w ago | Court Ruling | $419.38 $425.28 | ▲ +1.41% | ▲ +2.08% | $439.26 (+4.74%) |
Aug 13, 2026 10w ago | Insider Cluster | $415.21 $419.38 | ▲ +1.00% | ▲ +1.48% | $439.26 (+5.79%) |
Aug 11, 2026 10w ago | Court Ruling | $416.18 $417.84 | ▲ +0.40% | ▼ −0.30% | $439.26 (+5.55%) |
Aug 7, 2026 11w ago | Insider Cluster | $417.20 $414.30 | ▼ −0.70% | ▼ −0.38% | $439.26 (+5.29%) |
Aug 7, 2026 11w ago | Insider Cluster | $417.20 $414.30 | ▼ −0.70% | ▼ −0.38% | $439.26 (+5.29%) |
Aug 7, 2026 11w ago | Insider Cluster | $417.20 $414.30 | ▼ −0.70% | ▼ −0.38% | $439.26 (+5.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers